Value Dossier

Understanding the Clinical and Financial Impact of Early Intervention in AKI Risk Assessment

This resource walks you through the data, protocols, and strategies that enable earlier acute kidney injury (AKI) risk assessment to help reduce length of stay (LoS), readmissions, and avoidable AKI-related costs.

Value dossier booklet.

Download the Dossier
It's completely free.

ICU TEAMS ARE OVERWHELMED BY COMPLICATIONS

Top hospitals are transforming AKI care with early, evidence-backed detection.

KEY TAKEAWAYS:

  • Traditional AKI markers might miss early risk.
  • Kidney stress biomarkers can asses AKI risk earlier.
  • VIDAS® NEPHROCHECK® [TIMP-2•IGFBP-7] can help reduce severe AKI up to 89%.
  • Real-world LoS, mortality, and cost improvements.
  • Better alignment with new cardiac surgery guidelines.

VIDAS NEPHROCHECK offers an evidence-based tool for AKI risk assessment, enabling earlier detection of kidney stress and supporting timely intervention in ICU patients. This guide gives you the data, impact, and confidence to move forward.

89% reduction in moderate-to-severe AKI with VIDAS NEPHROCHECK.1 Kidney biomarkers significantly increase 48-72 hours before creatinine rises.2

References

  1. Engelman DT, Crisafi C, Germain M, et al. Using urinary biomarkers to reduce acute kidney injury following cardiac surgery. J Thorac Cardiovasc Surg. 2020;160(5):1235-1246.e2. doi:10.1016/j.jtcvs.2020.03.125
  2. Moledina DG, Parikh CR. Phenotyping of Acute Kidney Injury: Beyond Serum Creatinine. Semin Nephrol. 2018;38(1):3-11.